Lilly, Pfizer offer ED ad schedules to parents' group; EEOC sues Abbott for age discrimination;

 @FiercePharma: Buried data shows Pfizer psych drug 'ineffective'. Story

> Eli Lilly and Pfizer will provide a media advocacy group with schedules of its television advertisements for erectile dysfunction remedies Cialis and Viagra after complaints that the ads aren't appropriate for children's viewing. Report

> A former Abbott Laboratories sales rep's complaint of age discrimination has turned into an Equal Employment Opportunity Commission lawsuit against the drugmaker; Abbott says it values a "diverse" workforce and says the complaint is "without merit." Item

> Swiss biotech company Actelion (ATLN.VX) is close to hiring boutique investment bank Moelis & Co to advise it on alternatives as takeover rumors swirl around the company, a source familiar with the situation said. Story

> GlaxoSmithKline is to donate 400 million tablets a year to treat children in Africa at risk of intestinal worms, which are said to cause more ill-health in school-age children than any other infection. Report

> Shares in Dublin, Ireland-based drugmaker Shire were given a little nudge yesterday after it successfully snapped up Belgian biotech Movetis NV following its move on the group in September with an offer for €19 per share. Article

> Siga Technologies said the U.S. Department of Health and Human Services intends to give it a contract to deliver 1.7 million courses of its smallpox treatment for the Strategic National Stockpile. Report

> Baxter International will combine its delivery business, which supplies IV infusion systems and intravenous solutions, with its renal products unit in a new Medical Products division. News

> The FDA is to collaborate with the WHO to build a global surveillance and monitoring system for combating falsified medicines and breaches of the supply chain. Item

 @FierceBiotech: Advisory panel rejections carry the greatest clout at the FDA. Report | Follow @FierceBiotech

 @JohnCFierce:  SIGA Tech lands, or almost lands, $2.8B antiviral contract from HHS, shares skyrocket 46 percent. News | Follow @JohnCFierce

Biotech News

> BioCryst shifts HQ to Durham as it ramps up commercial ops. Story 

> Sanofi insiders: Proxy fight could seal the Genzyme deal. News 

> Loyal Arena investors battling for diet drug approval. Report 

> Genzyme sees signs of remission in 5-year MS drug data. Item 

> Third Rock partners on $33M Series A for diagnostic startup. Article 

Vaccines News

> WHO receives $10.4M in grants. Report

> Group uses comic books to explain TB vax trial. Story

> Inviragen, PharmaJet land $15.5M for needle-free dengue vax. Article 

> Experts: 'Donor fatigue' possible if polio not eradicated. Item 

Manufacturing News

> Report: Officials wrongly closed Indian vax plants. Story

> European directive targets pharma gangsters. Article

> Pill mix-up leads to cancer drug recall. News

> Cancer vax maker tests closed-bag process. Story 

> China proposes boost to supply chain security. Report

And Finally... A new report shows that vaccination rates among 2-year-olds covered by private insurance plans dipped by almost four percentage points last year. Article

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.